Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
| ▸ | EPS15 | P42566 | 1/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.48 |
| ▸ | NNMT | P40261 | 4/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24218684 | 1.00 | PLAU (0.52) | PLAUKLKB1CD274ITGB3ITGB1 | |
| SCHEMBL23743621 | 0.94 | PLAU (0.50) | PLAUKLKB1CD274ITGB3ITGB1 | |
| SCHEMBL24218672 | 0.93 | CD274 (0.55) | PLAUKLKB1CD274ITGB3ITGB1 | |
| SCHEMBL24218677 | 0.93 | ITGB3 (0.56) | PLAUKLKB1CD274ITGB3ITGB1 | |
| SCHEMBL23743622 | 0.92 | KLKB1 (0.50) | PLAUKLKB1CD274ITGB3ITGB1 | |
| SCHEMBL24218656 | 0.92 | KLKB1 (0.56) | PLAUKLKB1CD274PDCD1ALB | |
| SCHEMBL24218670 | 0.91 | CD274 (0.48) | PLAUKLKB1CD274ITGB3ITGB1 | |
| SCHEMBL24218680 | 0.90 | KLKB1 (0.51) | PLAUKLKB1CD274PDCD1ALB | |
| SCHEMBL24218602 | 0.89 | CD274 (0.53) | PLAUKLKB1CD274ITGB3ITGB1 | |
| SCHEMBL24218597 | 0.89 | CD274 (0.53) | PLAUKLKB1CD274ITGB3ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024981-A1 | CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | PLAU 148/4885KLKB1 67/4885CD274 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.